GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Entera Bio Ltd.
Entera Bio is a biotech company developing a technology for the oral delivery of large molecules. Its stock price represents a venture capital bet on the success of this platform. The chart reflects high volatility associated with clinical trial results.
Share prices of companies in the market segment - Pharma other
Entera Bio is a biotechnology company developing a technology for the oral delivery of large molecules, such as proteins and peptides, which could replace injections in the treatment of many diseases. We have classified it in the "Other Pharma" segment. The chart below shows the overall dynamics in the innovative pharmaceutical technology sector, where new methods of drug delivery are being explored.
Broad Market Index - GURU.Markets
Entera Bio is an Israeli company developing technology for the oral delivery of large drug molecules, such as hormones. As an innovator in this field, it is included in our GURU.Markets index. The chart below shows the overall market trend. See how investors are valuing this breakthrough technology.
Change in the price of a company, segment, and market as a whole per day
ENTX - Daily change in the company's share price Entera Bio Ltd.
For Entera Bio Ltd., which develops oral protein drugs, daily price changes are a measure of enormous volatility. This metric reflects extreme sensitivity to clinical trial data and is key to biotech risk assessment formulas.
Daily change in the price of a set of shares in a market segment - Pharma other
For Entera Bio Ltd., which develops oral protein drugs, daily price changes are a measure of enormous volatility. This metric reflects extreme sensitivity to clinical trial data and is key to biotech risk assessment formulas.
Daily change in the price of a broad market stock, index - GURU.Markets
Entera Bio has developed a technology for the oral delivery of large drug molecules. It's a potentially revolutionary biotech, and its shares are driven by research news. Their high volatility reflects the significant risks and expectations affecting the entire market.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Entera Bio Ltd.
For Entera Bio Ltd., the year-to-date performance is a story about the development of its platform for the oral delivery of large molecules. Its 12-month market cap depends entirely on clinical trial data for its lead candidate for the treatment of hypoparathyroidism. Success could be a breakthrough, allowing the company to replace injections with tablets.
Annual dynamics of market capitalization of the market segment - Pharma other
Entera Bio Ltd. is a biotechnology company developing oral delivery technology for large molecules typically administered by injection. Its stock price is highly volatile, reflecting investor confidence in its breakthrough potential and clinical trial results.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Entera Bio is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of its oral drug delivery platform. The company's stock chart lives in a world of its own.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Entera Bio Ltd.
Entera Bio is developing a technology for the oral delivery of large drug molecules. Its monthly performance is entirely dependent on the results of its clinical trials. News of success or failure in trials, particularly for its lead drug for hypoparathyroidism, are binary events.
Monthly dynamics of market capitalization of the market segment - Pharma other
Entera Bio Ltd. is a clinical-stage biotechnology company specializing in the development of oral protein-based drugs. The dynamics of its sector, shown in the chart, reflect the risks of R&D. Against this backdrop, it is possible to assess the progress of its patented technology, which allows drugs typically administered by injection to be taken as tablets, in clinical trials.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Entera Bio is a biotech company developing tablet versions of injectable medications. Its shares are driven by news of the success of its technology platform. The chart will show high volatility and weak correlation with the market as investors evaluate the potential of this revolutionary technology.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Entera Bio Ltd.
Entera Bio, a company developing oral delivery technology for large drug molecules, is experiencing high volatility. Weekly stock performance is driven by news about clinical trials of its platform, where success could revolutionize drug delivery.
Weekly dynamics of market capitalization of the market segment - Pharma other
Entera Bio is developing a technology for the oral delivery of large drug molecules. This could revolutionize the treatment of many diseases. This chart compares the market reaction to Entera's news with overall trends in the pharmaceutical sector and helps us understand the extent of investor confidence in its breakthrough platform.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Entera Bio develops oral drug delivery technology. Its shares follow the rhythm of development news. The chart will show how independent ENTX's performance is from general market fluctuations, driven by its unique scientific and commercial news.
Market capitalization of the company, segment and market as a whole
ENTX - Market capitalization of the company Entera Bio Ltd.
Entera Bio's stock price is a financial bet on the oral delivery of large molecules. The company's market cap reflects hopes for its technology, which aims to make injectable drugs like growth hormones available as tablets. Its volatility reflects the company's complex clinical trials and potential revolution in drug delivery.
ENTX - Share of the company's market capitalization Entera Bio Ltd. within the market segment - Pharma other
Entera Bio's market share in the pharmaceutical sector is based on its oral delivery technology for large molecules. Its market share is driven by the potential to transform injectable drugs into convenient tablets, which could revolutionize the treatment of many diseases, including osteoporosis.
Market capitalization of the market segment - Pharma other
Entera Bio is developing technology for the oral delivery of large molecules, such as hormones. The chart below shows the market capitalization of the entire pharmaceutical industry. Its dynamics provide a backdrop for Entera's valuation, whose technology could solve a long-standing problem in the pharmaceutical industry.
Market capitalization of all companies included in a broad market index - GURU.Markets
Entera Bio is developing technology for the oral delivery of large molecules, such as proteins, to treat diseases. Its market capitalization is a bet on solving this complex problem. The chart below shows the economic weight of companies working on creating the "pills of the future."
Book value capitalization of the company, segment and market as a whole
ENTX - Book value capitalization of the company Entera Bio Ltd.
Entera Bio, a company developing oral medications, has a book value that represents its equity. The chart below tells the story of its financial resources for clinical trials. Its dynamics reflect the pulse of its ambitious research project to transform injections into tablets.
ENTX - Share of the company's book capitalization Entera Bio Ltd. within the market segment - Pharma other
Entera Bio is developing a technology for the oral delivery of large molecules. Its value lies in its scientific platform. The share of tangible assets will be minimal, typical for an R&D company whose primary capital is intellectual rather than production.
Market segment balance sheet capitalization - Pharma other
Entera Bio is a biotech company developing oral drug delivery technology. Its value lies in its patents and clinical data, not its manufacturing plants. This is a classic "light" biotech model. The chart below illustrates how capital-intensive the pharmaceutical industry as a whole is.
Book value of all companies included in the broad market index - GURU.Markets
Entera Bio's balance sheet consists of intellectual property for oral delivery technology for large molecules, such as hormones and proteins. The company's assets represent capital invested in a platform that could replace injections with pills for the treatment of diseases such as osteoporosis.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Entera Bio Ltd.
Entera Bio develops technology for the oral delivery of large molecules, such as hormones. The company has no tangible assets. Its market capitalization is a bet on its platform and its leading candidate for the treatment of hypoparathyroidism. The chart reflects the risks and potential of this technology, which could change the way many medications are taken.
Market to book capitalization ratio in a market segment - Pharma other
Entera Bio is developing technology for the oral delivery of large drug molecules. It is a clinical-stage company. Its entire value stems from faith in its technological platform. The chart shows how much its market valuation, based on this potential, exceeds its current tangible assets.
Market to book capitalization ratio for the market as a whole
Entera Bio is a biotech company developing technology for the oral delivery of large drug molecules. The chart shows how the market values a company with a platform technology. Its market capitalization reflects its bet on developing tablet versions of drugs currently available only as injections.
Debts of the company, segment and market as a whole
ENTX - Company debts Entera Bio Ltd.
Entera Bio is developing a technology for the oral delivery of large drug molecules. This is a complex scientific challenge requiring lengthy and expensive research. This chart shows how the company is raising capital, including debt, to fund its clinical programs and validate its innovative platform.
Market segment debts - Pharma other
Entera Bio is a biopharmaceutical company developing a technology for the oral delivery of large molecules, such as proteins. This could radically change the treatment of many diseases. The chart provides insight into the financial norms of the industry, where companies are raising significant capital to conduct clinical trials of their breakthrough, but risky, technology.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Entera Bio Ltd.
Entera Bio is a biotech company developing a technology for the oral delivery of large drug molecules typically administered by injection. This is a potentially breakthrough, but risky, development. This chart illustrates the company's reliance on debt to finance its expensive clinical trials and research.
Market segment debt to market segment book capitalization - Pharma other
The development of oral protein therapies, like Entera Bio's, could revolutionize the treatment of many diseases. This chart illustrates how the biotech sector is funding such breakthrough technologies. It allows us to appreciate how Entera Bio's financial model, with its unique delivery technology, differs from that of other pharmaceutical companies.
Debt to book value of all companies in the market
Entera Bio is developing a technology for the oral delivery of large drug molecules, which could be a breakthrough. Decades of research require significant investment. The chart shows how their debt obligations for this purpose compare to the overall capital structure of the market.
P/E of the company, segment and market as a whole
P/E - Entera Bio Ltd.
This valuation for Entera Bio Ltd., a biotech company developing oral delivery technology for large-molecule drugs, reflects investor expectations. Its valuation is based on faith in its platform, which could eliminate the need for injections for patients, representing a huge potential market.
P/E of the market segment - Pharma other
This indicator represents the average valuation for the biotech sector in which Entera Bio operates. It reflects the overall level of hope and expectation in the development of new drug delivery systems. The chart serves as a barometer of investor confidence in the future of oral technologies.
P/E of the market as a whole
Entera Bio is developing a technology for the oral delivery of large molecules, such as hormones. Its lead candidate is a pill for the treatment of hypoparathyroidism that could replace injections. This chart illustrates the market's interest in breakthrough technologies. It helps us understand whether the market believes Entera Bio can solve the complex scientific challenge of oral protein delivery, and the risks involved.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Entera Bio Ltd.
Entera Bio is a biotech company developing a platform for the oral delivery of large molecules, such as proteins, which typically require injections. Its lead program is aimed at treating hypoparathyroidism. The future depends on the success of this technology. This chart reflects investors' speculative expectations regarding its potential to achieve breakthroughs in drug delivery.
%20P%2FE%20Entera%20Bio%20Ltd.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Entera-Bio-Ltd.&v=1772577188273 "Chart of the company's future (projected) P/E Entera Bio Ltd.")
Future (projected) P/E of the market segment - Pharma other
Entera Bio is a biotech company developing a technology for the oral delivery of large molecules, such as hormones. This could replace injections with pills. The chart reflects expectations for the biotech sector, helping to assess the market's confidence in the scientific potential and commercial prospects of this platform.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20other&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-other&v=1772577188378 "Future (projected) P/E graph of the market segment - Pharma other")
Future (projected) P/E of the market as a whole
Entera Bio is a biotech company developing technology for the oral delivery of large molecules, such as hormones and proteins, currently administered only by injection. This chart of overall expectations demonstrates investor appetite for breakthrough technologies. Market optimism is essential for funding such ambitious projects, which have the potential to radically change the treatment of many diseases.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772577188447 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Entera Bio Ltd.
Entera Bio develops technology for the oral delivery of large molecules, such as proteins. This chart shows the financial health of the company, which is working to solve a complex pharmaceutical problem. Future profitability depends on the success of clinical trials and partnerships with companies seeking to develop oral versions of their injectable drugs.
Profit of companies in the market segment - Pharma other
Zhibao Technology Inc. is a Chinese company providing digital solutions for insurance brokers. Its profitability depends on the pace of digitalization in China's insurance market. This chart illustrates how technology platforms serving traditional industries can grow alongside their clients, helping them adapt to the new reality.
Overall market profit
Entera Bio is a biotech company developing technology for the oral delivery of large molecules, such as hormones. The company is focused on treating bone diseases. Its success depends on proving the efficacy of its platform in clinical trials, which could lead to a breakthrough in drug delivery.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Entera Bio Ltd.
Entera Bio is a biotech company developing technology for the oral delivery of large molecules, such as hormones. Its revenue forecast hinges on the success of clinical trials, particularly its drug for the treatment of hypoparathyroidism. This chart reflects analysts' speculative expectations for its technology platform.
%20profit%20of%20the%20company%20Entera%20Bio%20Ltd.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Entera-Bio-Ltd.&v=1772577188649 "Graph of future (projected) profit of the company Entera Bio Ltd.")
Future (predicted) profit of companies in the market segment - Pharma other
Entera Bio is developing a technology for the oral delivery of large molecules, such as hormones and proteins, currently administered only by injection. This could radically change the treatment of many diseases. This chart shows profitability forecasts for the pharmaceutical sector. It reflects the high stakes and potential of this technology, which could make treatment more convenient for millions of patients.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20other&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-other&v=1772577188682 "Graph of future (predicted) profits of companies in a market segment - Pharma other")
Future (predicted) profit of the market as a whole
Entera Bio is developing a technology for the oral delivery of large drug molecules. This could revolutionize the treatment of many diseases. Corporate profit projections, as shown in this chart, influence the investment climate and investor willingness to fund such long-term, high-risk, but potentially breakthrough pharmaceutical platforms.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772577188725 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Entera Bio Ltd.
Entera Bio is a biotech company developing a platform for the oral delivery of large molecules, such as proteins. Its lead development is aimed at creating a tablet for the treatment of hypoparathyroidism. The chart reflects investor valuation of its technology, which has the potential to revolutionize the treatment of many diseases but does not yet have any approved products.
P/S market segment - Pharma other
Entera Bio Ltd. is a clinical-stage biopharmaceutical company developing a platform for the oral delivery of large molecules, such as proteins, to treat diseases. This chart shows the average valuation in the sector, providing insight into the market's perception of the revenue potential of Entera Bio's breakthrough drug delivery technology.
P/S of the market as a whole
Entera Bio is developing a technology for the oral delivery of large molecules, such as proteins, which could replace injections. A key development is aimed at treating hypoparathyroidism. This chart, showing average valuations, clearly highlights the gap between the valuations of traditional businesses and companies developing breakthrough drug delivery systems.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Entera Bio Ltd.
Entera Bio develops technology for the oral delivery of large molecules, such as proteins, typically administered by injection. This chart reflects investors' confidence in the potential of this platform. The valuation is based on future revenue from its drugs, particularly an oral form of a hypoparathyroidism medication, should clinical trials be successful.
%20P%2FS%20Entera%20Bio%20Ltd.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Entera-Bio-Ltd.&v=1772577188849 "The graph of the company's future (projected) P/S Entera Bio Ltd.")
Future (projected) P/S of the market segment - Pharma other
Entera Bio Ltd. is developing a technology for the oral delivery of large molecules, such as proteins, typically administered by injection. Its lead candidate is designed to treat hypoparathyroidism. The chart shows how investors estimate Entera Bio's future sales, reflecting the potential of its platform to create more patient-friendly medications.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20other&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-other&v=1772577188872 "Future (projected) P/S market segment graph - Pharma other")
Future (projected) P/S of the market as a whole
Market sentiment regarding future revenue depends on innovations in drug delivery methods. Entera Bio, like Oramed, is developing technology for the oral delivery of large molecules, such as hormones and antibodies. Their work in this complex area supports investor confidence that scientific breakthroughs can dramatically improve existing treatments.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772577188879 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Entera Bio Ltd.
Entera Bio is a clinical-stage company developing a platform for the oral delivery of large molecules, such as proteins. The company does not yet have commercial sales revenue. Its financial chart reflects revenue from collaborations and investments in its cutting-edge research aimed at replacing injections with tablets.
Sales of companies in the market segment - Pharma other
Entera Bio is a biotechnology company developing oral delivery technology for large molecules, such as hormones and proteins, typically administered by injection. This graph shows the overall revenue in the pharmaceutical industry. It illustrates the enormous need to replace injections with pills, which could dramatically improve the quality of life for millions of patients.
Overall market sales
Entera Bio is a biotech company developing technology for the oral delivery of large molecules, such as proteins, typically administered by injection. Its lead program is aimed at treating hypoparathyroidism. Success depends on clinical data. This overall economic climate impacts the availability of funding for companies with breakthrough but risky technologies.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Entera Bio Ltd.
Entera Bio is developing technology for the oral delivery of large molecules, such as hormones. The company is focused on the treatment of osteoporosis and hypoparathyroidism. The future depends on the success of clinical trials. The chart shows speculative analyst forecasts, which are betting on a breakthrough in the delivery of complex biologic drugs.
%20sales%20of%20the%20company%20Entera%20Bio%20Ltd.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Entera-Bio-Ltd.&v=1772577188946 "Schedule of future (projected) sales of the company Entera Bio Ltd.")
Future (projected) sales of companies in the market segment - Pharma other
Entera Bio is a biopharmaceutical company developing technology for the oral delivery of large molecules, such as proteins, typically administered by injection. This could revolutionize the treatment of many diseases. This chart displays projected sales for the entire pharmaceutical sector, highlighting the overall expectations for the development of new drug delivery systems.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20other&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-other&v=1772577188972 "Schedule of future (projected) sales of companies in the market segment - Pharma other")
Future (projected) sales of the market as a whole
Entera Bio is a biotechnology company developing a platform for the oral delivery of large drug molecules, such as hormones. The company's success depends on clinical evidence of the efficacy of its technology. This overall economic activity schedule impacts the availability of capital to finance risky but potentially breakthrough medical developments.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772577188999 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Entera Bio Ltd.
Entera Bio is developing a technology for the oral delivery of large drug molecules. This indicator reflects its financial progress during the R&D stage. It demonstrates the level of investment in clinical trials, which are key to validating the effectiveness of its platform and securing partnerships with major pharmaceutical companies.
Market segment marginality - Pharma other
Entera Bio is developing a technology for the oral delivery of large molecules, such as proteins, which could replace injections. The profitability of this platform depends on the success of clinical trials. This metric reflects the company's operational structure and level of investment in its innovative drug delivery technology.
Market marginality as a whole
Entera Bio is a biotech company developing a technology for the oral delivery of large molecules, such as proteins. Their lead candidate is a tablet for the treatment of hypoparathyroidism. Their future depends entirely on the success of clinical trials. This overall profitability curve is not directly relevant to them, but it does impact the overall investment climate in biotech.
Employees in the company, segment and market as a whole
Number of employees in the company Entera Bio Ltd.
Entera Bio is developing a technology for the oral delivery of large molecules, potentially replacing injections. The company is in the clinical stage and has a small staff. This chart shows the dynamics of the team of scientists and clinical trial specialists working to validate the efficacy of this potentially breakthrough platform.
Share of the company's employees Entera Bio Ltd. within the market segment - Pharma other
Entera Bio develops technology for the oral delivery of large molecules, such as hormones. This chart shows the concentration of unique pharmacologists and chemists. The proportion of these specialists reflects its ambitious goal of transforming injectable drugs into convenient tablets, changing approaches to treatment.
Number of employees in the market segment - Pharma other
Entera Bio Ltd. is a company developing technology for the oral delivery of large molecules, such as hormones and proteins. This chart shows overall employment in the pharmaceutical sector. It illustrates the potential of Entera Bio's technology to create tablet versions of drugs currently available only as injections, which could radically change the treatment of many diseases.
Number of employees in the market as a whole
Entera Bio is a company developing technology for the oral delivery of large molecules, such as proteins, which could replace injections. This represents a potential breakthrough for many drugs. This employment graph reflects the contribution of the biotech sector, where companies like Entera create highly skilled jobs for scientists working to solve fundamental problems in pharmacology.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Entera Bio Ltd. (ENTX)
Entera Bio Ltd. develops technology for the oral delivery of large molecules, such as hormones and other biologics. This chart shows a high market capitalization per employee, typical for a biotech company with a breakthrough technology. The market is evaluating the platform's potential to disrupt the multi-billion dollar injectable drug market, not the team's current performance.
%20of%20the%20company%20Entera%20Bio%20Ltd.%20(ENTX)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Entera-Bio-Ltd.-ENTX&v=1772577189364 "Chart of market capitalization per employee (in thousands of dollars) of the company Entera Bio Ltd. (ENTX)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma other
Entera Bio is developing a technology for the oral delivery of large molecules, potentially replacing injections. This is a potentially breakthrough platform in pharmaceuticals. This metric reflects the enormous value the market sees in their technology. The high market capitalization per employee reflects investors' bet that their developments will radically change the treatment of many diseases.
%20by%20market%20segment%20-%20Pharma%20other&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-other&v=1772577189380 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma other")
Market capitalization per employee (in thousands of dollars) for the overall market
Entera Bio Ltd. is developing technology for the oral delivery of large drug molecules. It is a development-stage biotech company. Its valuation reflects the success of its platform. Its high market capitalization per employee reflects its enormous potential if the company can create tablets that replace injections for a wide range of medications.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772577189414 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Entera Bio Ltd. (ENTX)
Entera Bio (ENTX) is a biotech R&D company. Like Oramed, they are developing technology for the oral delivery of large molecules (drugs typically administered by injection). This chart shows their capital burn rate—the net loss (research costs) per scientist.
%20Chart%20Entera%20Bio%20Ltd.%20(ENTX)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Entera-Bio-Ltd.-ENTX&v=1772577189418 "Company Profit Per Employee (in thousands of dollars) Chart Entera Bio Ltd. (ENTX)")
Profit per employee (in thousands of dollars) in the market segment - Pharma other
Entera Bio is developing a technology for the oral delivery of large drug molecules. For a company in the R&D stage, this metric is irrelevant. The graph represents the industry norm. If successful, Entera will be able to license its platform, which would generate colossal profits with minimal staff, far exceeding any industry benchmark.
%20in%20the%20market%20segment%20-%20Pharma%20other&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-other&v=1772577189466 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma other")
Profit per employee (in thousands of dollars) for the market as a whole
Entera Bio (ENTX) is developing a technology for the oral (pill form) delivery of large molecules, such as hormones, typically administered by injection. This R&D is complex. This graph shows that the company is in the development stage. Its profit per employee is negative, as the team has not yet brought the product to market.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772577189528 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Entera Bio Ltd. (ENTX)
For Entera Bio, a company developing oral delivery technology for large-molecule drugs, this graph reflects the clinical trial stage. Future revenue growth per employee depends entirely on the success of its platform and partnerships with pharmaceutical companies to create tablet versions of injectable drugs.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Entera-Bio-Ltd.-ENTX&v=1772577189624 "Sales chart per company employee Entera Bio Ltd. (ENTX)")
Sales per employee in the market segment - Pharma other
Entera Bio is a biopharmaceutical company developing a technology for the oral (in capsules) delivery of large drug molecules. It is an R&D platform. This metric reflects the average revenue per employee in the segment. It helps assess how productive their R&D team is in commercializing their technology compared to other pharmaceutical companies.
Sales per employee for the market as a whole
Entera Bio (ENTX) is a biopharmaceutical company developing oral (capsule-based) delivery technology for large-molecule drugs. This metric is an indicator of the future for them. Zero values currently reflect the R&D stage. A rising metric will indicate a commercial breakthrough and the success of their unique delivery platform, or the conclusion of major partnerships.
Short shares by company, segment and market as a whole
Shares shorted by company Entera Bio Ltd. (ENTX)
Entera Bio is a biotech company attempting to develop a technology for the oral (in tablets) delivery of large molecules, such as hormones. This is the "Holy Grail" of pharmaceutical companies, and many have failed. This chart reflects investor bets that Entera's technology will also prove ineffective and its clinical trials will fail.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Entera-Bio-Ltd.-ENTX&v=1772577189739 "Short Shares Chart for the Company Entera Bio Ltd. (ENTX)")
Shares shorted by market segment - Pharma other
Entera Bio (ENTX) is a company developing oral delivery technology for large molecules (like Oramed), focused on osteoporosis drugs. This chart shows the aggregate short interest in the speculative pharmaceutical development sector. It reflects deep market skepticism about the viability of their platform for oral delivery of complex drugs.
Shares shorted by the overall market
Entera Bio is a clinical-stage biotech company. Its value reflects its hope for future success. When this overall pessimism indicator rises, investors are less inclined to hope. They are dumping unprofitable companies en masse, as they require constant refinancing for R&D.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Entera Bio Ltd. (ENTX)
For Entera Bio, this chart is a barometer of faith in the oral delivery of complex drugs. The company is trying to create tablets based on drugs that can currently only be injected (for example, for the treatment of osteoporosis). Success would be revolutionary. Positive trial data leads to "overheating" (above 70). Doubts that the technology will work on a large scale lead to "oversold" (below 30).
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Entera-Bio-Ltd.-ENTX&v=1772577189792 "RSI 14 indicator chart for the company's stock Entera Bio Ltd. (ENTX)")
RSI 14 Market Segment - Pharma other
Entera (ENTX) — a "pill" instead of an injection (Israel). They (like Oramed) are *pioneers* in developing *oral* (in tablets) *delivery* of "protein" drugs (for example, growth hormone). The "Pharma Other" (biotech) sector thrives on news. RSI_14_Seg shows the "temperature" of *the entire* segment. It is vital to understand: is ENTX's growth due to their R&D or is *the entire* biotech "overheated"?
RSI 14 for the overall market
Entera Bio (ENTX) is a biotech company. Like everything in its sector, it's critically dependent on this chart. Market euphoria is an opportunity to easily raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast ENTX (Entera Bio Ltd.)
Entera Bio is an Israeli company developing technology for the oral (in capsules) delivery of large molecules (proteins) typically administered by injection. This chart shows the speculative average price target from analysts based on their belief in this R&D platform, particularly for the treatment of osteoporosis.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-ENTX-Entera-Bio-Ltd.&v=1772577189891 "A chart showing analyst consensus forecasts for the expected stock price. ENTX (Entera Bio Ltd.)")
The difference between the consensus estimate and the actual stock price ENTX (Entera Bio Ltd.)
ENTX - Entera Bio is a biotech company developing a platform for the oral (tablet) delivery of large molecules (proteins), which typically can only be injected. This chart shows the gap between the market estimate and the analyst target price. It indicates whether experts believe in this drug delivery technology.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-ENTX-Entera-Bio-Ltd.&v=1772577189911 "A chart showing the difference between the consensus forecast and the actual stock price. ENTX (Entera Bio Ltd.)")
Analyst consensus forecast for stock prices by market segment - Pharma other
Entera Bio (ENTX) is an Israeli company (like Oramed) developing oral (tablet) delivery technology for complex drugs (proteins), which are currently administered only by injection. This chart shows general expectations for the pharmaceutical sector. It reflects whether experts believe in a "pills instead of injections" breakthrough.
Analysts' consensus forecast for the overall market share price
Entera Bio is an Israeli company developing a platform for the oral (in tablets) delivery of "large" molecules (proteins) typically administered only by injection (for example, growth hormone). This chart shows the overall risk appetite. For Entera, a company with a breakthrough but risky technology, overall market optimism is critical to attracting capital for long-term clinical trials.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Entera Bio Ltd.
Entera Bio (ENTX) is another company chasing the Holy Grail. Their signature feature is a platform for the oral (pill) delivery of large molecules (proteins) that typically require injections. This chart is a pure R&D bet. Its valuation reflects the market's belief that their (previously failed) delivery technology (not the drug itself) will suddenly work.
AKIMA Market Segment Index - Pharma other
Entera Bio is an Israeli company developing a technology for the oral (in tablets) delivery of large molecules (proteins), typically administered only by injection. This chart shows the average index for the pharmaceutical sector. It allows one to assess how Entera Bio's risky but revolutionary platform compares to the average pharmaceutical company.
The AKIM Index for the overall market
Entera Bio is a biotech company developing a technology for the oral delivery of large molecules (tablets instead of injections), for example, for osteoporosis. This chart, reflecting the market average, provides a macro backdrop. It helps assess how this innovative platform compares to overall economic trends.
